Answers are grounded in this paper and cite their sources.
Despite the development of Coronavirus Disease 2019 (COVID-19) vaccines, the search for a definitive cure continues. 6′-Hydroxy justicidin B (6′-HJB), found in Justicia procumbens and used in Chinese medicine for its antiviral properties, shows promise as a therapeutic candidate against COVID-19. Nevertheless, it is crucial to establish its safety profile before clinical trials. This study evaluated its safety through non-clinical Good Laboratory Practice genotoxicity and rodent toxicity studies. The results indicated that 6′-HJB is not genotoxic, supporting its safety for future clinical use. The compound exhibited a low risk of DNA damage, a critical concern in drug development. Extensive toxicity studies, including single and repeated oral doses in Sprague Dawley rats, showed that the lethal dose of 6′-HJB exceeded 2000 mg/kg, with no observed adverse effects at this level. Safety data from genotoxicity and rodent toxicity studies strongly support further investigation of 6′-HJB as a novel treatment for COVID-19. 6′-HJB is expected to serve as a promising therapeutic option for overcoming future emerging viral infectious diseases. • GLP-compliant genotoxicity and toxicity tests established 6′-HJB safety. • 6′-HJB showed no genotoxic effects in regulatory-standard safety assays. • Oral doses up to 2000 mg/kg caused no mortality or adverse findings. • Sprague–Dawley rat studies confirmed non-lethal and non-toxic outcomes. • Results support 6′-HJB as a safe candidate for future clinical development.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: